scholarly journals A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China

2022 ◽  
Author(s):  
Hai-Yan Tu ◽  
Jifeng Feng ◽  
Meiqi Shi ◽  
Jun Zhao ◽  
Yuyan Wang ◽  
...  
Keyword(s):  
Final Analysis ◽  
Open Label ◽  
Phase Iiib ◽  
Egfr Tki

scholarly journals P2.01-99 A Phase IIIb Open-Label Study of Afatinib in EGFR TKI-Naïve Patients with EGFR Mutation-Positive NSCLC: Final Analysis

2019 ◽  
Vol 14 (10) ◽  
pp. S679-S680 ◽  
Author(s):  
Y. Wu ◽  
H. Tu ◽  
J. Feng ◽  
M. Shi ◽  
J. Zhao ◽  
...  
Keyword(s):  
Egfr Mutation ◽  
Final Analysis ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Phase Iiib ◽  
Egfr Tki

scholarly journals Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC

2019 ◽  
Vol 30 ◽  
pp. ix161-ix162
Author(s):  
F. De Marinis ◽  
K.K. Laktionov ◽  
A. Poltoratskiy ◽  
I. Egorova ◽  
M. Hochmair ◽  
...  
Keyword(s):  
Interim Analysis ◽  
Egfr Mutation ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Phase Iiib ◽  
Egfr Tki

EP1.14-49 A Phase IIIb Open-Label Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Exploratory Biomarker Analysis

2019 ◽  
Vol 14 (10) ◽  
pp. S1050-S1051
Author(s):  
J. Wang ◽  
J. Zhao ◽  
H. Bai ◽  
X. Wang ◽  
Y. Wang ◽  
...  
Keyword(s):  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Biomarker Analysis ◽  
Phase Iiib ◽  
Egfr Tki

scholarly journals P2.14-58 A Phase IIIb, Open-Label Study of Afatinib in Caucasian EGFR TKI-Naïve Patients with EGFRm+ NSCLC: An Interim Analysis

2019 ◽  
Vol 14 (10) ◽  
pp. S853-S854
Author(s):  
F. De Marinis ◽  
K.K. Laktionov ◽  
A. Poltoratskiy ◽  
I. Egorova ◽  
M.J. Hochmair ◽  
...  
Keyword(s):  
Interim Analysis ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Phase Iiib ◽  
Egfr Tki

scholarly journals P3.01-036 A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: An Interim Analysis

2017 ◽  
Vol 12 (11) ◽  
pp. S2214 ◽  
Author(s):  
Y. Wu ◽  
H. Tu ◽  
J. Feng ◽  
M. Shi ◽  
J. Zhao ◽  
...  
Keyword(s):  
Interim Analysis ◽  
Open Label ◽  
Phase Iiib ◽  
Egfr Tki

scholarly journals A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis

2019 ◽  
Vol 30 ◽  
pp. ix153-ix154
Author(s):  
J. Wang ◽  
J. Zhao ◽  
H. Bai ◽  
X. Wang ◽  
Y. Wang ◽  
...  
Keyword(s):  
Egfr Mutation ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Biomarker Analysis ◽  
Phase Iiib ◽  
Egfr Tki

scholarly journals Afatinib in EGFR TKI-naïve patients with EGFR mutation-positive (EGFRm+) NSCLC: Interim analysis of a phase IIIb, multi-national, open-label study

2019 ◽  
Vol 30 ◽  
pp. v598-v599
Author(s):  
F. de Marinis ◽  
K.K. Laktionov ◽  
A. Poltoratskiy ◽  
I. Egorova ◽  
M. Hochmair ◽  
...  
Keyword(s):  
Interim Analysis ◽  
Egfr Mutation ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Phase Iiib ◽  
Egfr Tki

scholarly journals A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis

2019 ◽  
Vol 30 ◽  
pp. ix162-ix163
Author(s):  
R. Rosell ◽  
A. Poltoratskiy ◽  
M. Hochmair ◽  
K.K. Laktionov ◽  
R. Ramlau ◽  
...  
Keyword(s):  
Egfr Mutation ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Biomarker Analysis ◽  
Phase Iiib ◽  
Egfr Tki
Sign in / Sign up

Export Citation Format

Share Document